Trials / Completed
CompletedNCT00376584
Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Study to Evaluate the Efficacy of MK0524 to Improve Tolerability of Extended Release Niacin
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 825 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a 12-week clinical trial in lipid clinic patients for whom niacin therapy is appropriate to evaluate the efficacy of MK0524 to improve the tolerability of extended-release niacin. There will be 6 scheduled clinic visits and 3 treatment arms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-0524A | |
| DRUG | ER Niacin | |
| DRUG | Placebo |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2007-01-01
- Completion
- 2007-01-01
- First posted
- 2006-09-15
- Last updated
- 2017-02-16
Source: ClinicalTrials.gov record NCT00376584. Inclusion in this directory is not an endorsement.